Table 4.

Incidence of treatment-emergent adverse event.

Adverse event	Placebo n = 70	Remimazolam (2.5 mg) n = 71	Remimazolam (5.0 mg) n = 71	p Value
Hypoxia	16 (22.9%)	5 (7.0%)a	11 (15.5%)	0.032
Hypotension	22 (31.4%)	10 (14.1%)a	16 (22.5%)	0.048
Hypertension	17 (24.3%)	13 (18.3%)	12 (16.9%)	0.506
Tachycardia	0 (0.0%)	0 (0.0%)	1 (1.4%)	1.000
Bradycardia	14 (20.0%)	5 (7.0%)	9 (12.7%)	0.075
Nausea	6 (8.6%)	6 (8.5%)	5 (7.0%)	0.933
Vomiting	1 (1.4%)	1 (1.4%)	2 (2.8%)	1.000
Prolonged sedation	2 (2.9%)	0 (0%)	0 (0%)	0.108

Data are presented as number (%) and comparisons among groups were performed using Chi-square tests or Fisher’s exact tests. If statistical differences were identified, pairwise comparisons were performed with Bonferroni correction to account for multiple testing. Compared with Placebo group, ^ap < 0.05. Compared with Group Remimazolam (2.5 mg), ^bp < 0.05.